Snider William 4

What Happened
William Snider, a director of Harvard Bioscience, bought shares in open-market purchases on March 16 and March 17, 2026. He acquired 12,525 shares on 3/16 at a weighted-average price of $4.99 (prices ranged $4.85–$5.00) for about $62,500, and 8,475 shares on 3/17 at a weighted-average price of $4.85 (prices ranged $4.80–$4.95) for about $41,104 — a total of 21,000 shares costing roughly $103,604. These were purchases (reporting code P), which are generally interpreted as insider buying rather than selling.

Key Details

• Transaction dates and prices:
  • 2026-03-16: 12,525 shares @ weighted avg $4.99 (actual prices $4.85–$5.00) — $62,500. (Footnote F1)
  • 2026-03-17: 8,475 shares @ weighted avg $4.85 (actual prices $4.80–$4.95) — $41,104. (Footnote F2)
• Total purchased: 21,000 shares for ~ $103,604.
• Holdings noted in filing: Footnotes indicate the reported holdings include the March 16 and March 17 purchases and 11,000 restricted stock units that vest on December 17, 2026 (these RSUs reflect a 10-for-1 reverse split on March 13, 2026). (Footnotes F3, F4, F5)
• Method/code: P = open market or private purchase.
• Filing timeliness: Report filed 2026-03-18 for transactions on 2026-03-16–03-17; this was filed within the normal Form 4 reporting window (timely).

Context

• Purchases by directors can be seen as a positive signal but don’t prove future company performance; the filing is factual and does not state motivation.
• Note the March 13, 2026 10-for-1 reverse split adjusted previously reported RSU counts (110,000 → 11,000).